NEST's Prefilled Automatic Pen Injector (Three-Step) Guide

Overview: A Closer Look at NEST's Injection Pen Portfolio

Wuxi NEST Biotechnology Co., Ltd., operating under the brand name NEST, has built its business around a clear industry insight: the rising incidence of chronic diseases demands precision dosing and self-administration solutions that reduce clinical workload, minimize needle-stick injuries, and prevent medication waste. Since its strategic entry into the pharmaceutical packaging sector in 2018, the company has positioned itself as a one-stop provider of pharmaceutical packaging materials and drug delivery technologies, with a particular focus on injection and inhalation methods. Within this broader strategy, the Prefilled Automatic Pen Injector Assembly (Three-Step) occupies a defined place inside NEST's Injection Pen Line, a product category dedicated to self-administration solutions for chronic conditions such as diabetes and growth hormone deficiency.

Positioning Within the Injection Pen Line

NEST's Injection Pen Line is built around a shared objective: enabling patients to manage long-term conditions with devices that are safe, consistent, and manufactured to strict quality standards. The line includes multiple formats — the Disposable Pen Injector, TSA Disposable Pen Injector, SP Disposable Pen Injector, Self-locking Pen Injector (100 IU), Disposable Fixed-dose Pen Injector, the Reusable Pen Injector, and the two automatic assemblies: the Prefilled Automatic Pen Injector Assembly (Two-Step) and the Prefilled Automatic Pen Injector Assembly (Three-Step). Each format is designed to answer the same underlying pain points that define this product category: the high cost associated with reusable devices, the risk of cross-contamination, patient needle anxiety, and the manual force limitations that many patients face during self-injection.

The Three-Step assembly is part of the automatic, spring-driven family of devices within this portfolio. Like its counterpart, the Two-Step assembly, it is engineered to reduce the physical and psychological barriers that patients encounter with self-administration — an approach consistent with NEST's stated value proposition of "empowering global advancement of drug-device combinations through smarter, more targeted treatment and precision dosing."

Manufacturing Foundation and Technical Standards

The Three-Step assembly benefits from the same manufacturing infrastructure that underpins NEST's entire Injection Pen Line. Production takes place within a dedicated 2,300 m² pen injector workshop, supported by 10,600 m² of Class 100,000 cleanrooms and 3,600 m² of Class 10,000 cleanrooms. This environment is maintained by a 76-person specialized quality team and a 50-person mold maintenance team, reflecting the scale of quality oversight applied across NEST's device manufacturing.

NEST's technical capabilities extend from design through inspection. The company operates an independent mold center and R&D team that has delivered over 300 precision molds, giving it direct control over component design rather than relying on third-party tooling. On the inspection side, NEST applies 100% multi-angle CCD camera inspection, a standard that is consistent across its device production. For components requiring sterilization, NEST maintains moist heat sterilization capabilities at SAL 10⁻⁶, a sterility assurance level applied within its broader primary packaging and device operations. Where applicable to prefillable formats within the portfolio, NEST also applies its proprietary cross-linked siliconization technology, developed to support stable gliding performance in syringes and cartridges.

Quality Assurance and Regulatory Compliance

Devices produced within NEST's Injection Pen Line, including the automatic pen injector assemblies, are manufactured under a certification framework that spans multiple international standards. NEST holds ISO 9001, ISO 13485, ISO 11137, ISO 15378, and IATF 16949 certifications, along with CE MDR Certification. The company has also achieved MDSAP Five-Country Certification, covering regulatory alignment across the USA, Canada, Australia, Japan, and Brazil.

For its pen injector and syringe product lines specifically, NEST secured multiple international certifications and licenses between 2023 and 2025, including US FDA 510(k) clearances (K240961, K240774), US DMF filings (No. 40744, No. 42439, No. 40922), Canada Medical Device Licenses (No. 113733, No. 112619), and a China Class II Medical Device Certificate. These filings, verified through third-party certification bodies such as TÜV SÜD for ISO 9001, 13485, and 11137, provide an external layer of validation for the quality systems governing NEST's automatic pen injector manufacturing.

Full Lifecycle Data Integrity

Beyond physical manufacturing, NEST applies full lifecycle validation and batch traceability across its device production, using batch numbers and retained samples to support quality tracking from production through delivery. This traceability framework, combined with compliance to RoHS and REACH regulations, is designed to give pharmaceutical partners visibility into the manufacturing history of the components they integrate into their own drug-device combination products.

Customer Base and Industry Application

The Prefilled Automatic Pen Injector Assembly (Three-Step), as part of the broader Injection Pen Line, is positioned to serve the industries NEST operates within: biopharmaceuticals, medical aesthetics, and life sciences. Its customer types include pharmaceutical companies producing insulin, GLP-1, and FSH therapies, along with research institutions and hospitals. These customer categories reflect the chronic-disease focus that defines NEST's Injection Pen Line, where consistent, low-force, self-administered dosing is a core requirement.

Global Manufacturing and Delivery Support

NEST supports its Injection Pen Line customers through a global operational footprint. Beyond its Wuxi headquarters and R&D center, the company maintains subsidiaries and warehouses in Woodbridge, NJ and Phoenix, AZ in the United States, Hendrik-Ido-Ambacht, Netherlands, Sharjah, UAE, Yokohama, Japan, and Istanbul, Turkey. This integrated warehousing network across the US, Europe, and Asia is intended to shorten lead times for international customers. NEST's service model for its device lines includes pre-sales customization, technical validation, automated assembly line planning, and global logistics — a one-stop structure covering R&D, production, pre-sterilization, and customized assembly.

Summary

The Prefilled Automatic Pen Injector Assembly (Three-Step) sits within a manufacturing and quality framework that spans independent mold design, cleanroom production, multi-standard certification, and global distribution. As part of NEST's Injection Pen Line, it reflects the company's broader strategic focus: providing pharmaceutical and life sciences partners with self-administration device options that are manufactured under internationally recognized quality systems and supported by a global delivery network. For organizations evaluating automatic pen injector components as part of a drug-device combination strategy, NEST's documented certifications, in-house tooling capability, and international footprint provide a transparent basis for technical and regulatory due diligence.